leisure time -WSS

leisure time

author：leisure time 2025-09-28 16:34:30 - browse：6

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. — Novo Nordisk via AP

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss.

The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%. That finding, which was the primary outcome the trial set out to study, was stronger than many were expecting and led Novo’s stock to surge.

But details of the study, including risk reductions for each specific heart complication, were not released until Saturday, when they were presented here — before a standing-room only crowd — as the first major session of the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Listen: Who gets the credit for GLP

hotspot

WSS

Asbestos, a deadly carcinogen, banned by EPA

Kaiser Permanente unions announce official strike date

Medicare drug price negotiation program allowed for now

Listen: Who gets the credit for GLP

Biogen shutters digital health group, ends Apple study, in cost cutting move

How one patient went off dialysis — and others can too

focus

leisure time

explore

Walensky prepares to leave CDC — and Congress — behind

Cigna to pay $172 million to settle Medicare Advantage fraud probe

New air purifier tech could be key to improving indoor air quality

Menendez indictment could see pharma lose a key ally

Duchenne breakthrough therapy leaves behind pioneering families

5 to watch: Tech startups trying to solve health care's staffing crisis

Duchenne breakthrough therapy leaves behind pioneering families

Menendez indictment could see pharma lose a key ally

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Orchard's therapy for neuron disease in children wins FDA approval

explore

Address the ethical violations that led to 'Three Identical Strangers'

Menendez indictment could see pharma lose a key ally

Readout Newsletter: Bluebird, CVS, Contineum

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Menendez indictment could see pharma lose a key ally

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Wikipedia

hotspot

focus

leisure time